Fig. 2
From: G2 checkpoint targeting via Wee1 inhibition radiosensitizes EGFRvIII-positive glioblastoma cells
Wee1 expression in EGFRvIII+ GBM patient samples. A Immunohistochemical detection of EGFRvIII and Wee1 expression in one representative GBM patient sample (GBM1) displaying heterogeneous EGFRvIII expression. Scale bars represent 50 µm and 5 mm (overview in the middle). B Immunohistochemical detection of EGFRvIII and Wee1 expression in four GBM patient samples displaying typical heterogeneous EGFRvIII expression. Scale bars represent 50 µm